The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery

Abstract

PurposeTo evaluate the efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace (0–5 cells) anterior chamber cells, following cataract surgery with posterior chamber intraocular lens implantation.MethodsThe study designed employed two Phase III, double-masked, placebo-controlled, multicenter clinical trials of 440 subjects, randomized to either bromfenac ophthalmic solution 0.07% (n=222) or placebo (n=218). Subjects self-dosed once daily, beginning 1 day before undergoing cataract surgery with intraocular lens implantation (day –1) and again on the day of surgery (day 0) and for 14 days postoperatively. Follow-up was on days 1, 3, 8, and 15. The outcome measures included the percentage of subjects with zero-to-trace anterior chamber cells at each visit, as determined by the percentage of subjects with ≤5 anterior chamber cells, overall anterior chamber cell grades, and summed ocular inflammation score (SOIS) (combined anterior chamber cell and flare scores).ResultsThe proportion of subjects with zero-to-trace anterior chamber cells was significantly higher in the bromfenac 0.07% group compared with the placebo group as early as day 3 (P=0.0007), continued at day 8 (P<0.0001), and through day 15 (P<0.0001). At day 15, 80.2% of subjects in the bromfenac 0.07% group achieved zero-to-trace anterior chamber cells compared with 47.2% of subjects who did so in the placebo group. The overall anterior chamber cell scores were significantly lower in the bromfenac 0.07% group compared with the placebo group at days 3, 8, and 15 (P<0.0001 at each visit). The SOIS were also significantly lower in the bromfenac group compared with the placebo group at days 3, 8, and 15 (P<0.0001 at each visit).ConclusionBromfenac ophthalmic solution 0.07%, dosed once daily was clinically effective in achieving zero-to-trace anterior chamber cell severity after cataract surgery and was superior to placebo in all anterior chamber cell severity and inflammation outcome measures.

Bromfenac 0.09% bioavailability in aqueous humor, prophylactic effect on cystoid macular edema, and clinical signs of ocular inflammation after phacoemulsification in a Mexican population

“…These results confirm that from the first day of instillation of bromfenac there is a potent effect inhibiting COX-2 and reducing the pain. Similar to other authors’ findings, 26 – 28 the signs of ocular inflammation (hyperemia, flare, cellularity, and chemosis) disappeared at the end of the intervention, even though the bromfenac concentration seemed to be low when compared to nepafenac.…”

Assessment of the eye surface and subjective symptoms after using 0.1% dexamethasone drops with and without preservatives in patients after cataract surgery

“…However, eyes receiving nonpreserved dexamethasone had a significantly higher mean AC cells score within this low grade (0.28 versus 0.07, p = 0.013). Clinically, this difference may be regarded as irrelevant because zero-to-trace (+ 0.5) anterior chamber cells are used in other clinical trials as one category for inflammation control following cataract surgery 27 . A possible explanation for slightly better inflammation control in the PD group is that dexamethasone suspension penetrates the cornea better than water solution.…”

The Use of Bromfenac Ophthalmic Solution in Clinical Practice (Literature Review)

“…Применение НПВС достаточно эффективно в профилактике и лечении МО после удаления катаракты как у пациентов с сахарным диабетом, так и без него [47][48][49][51][52][53][54][55][56].…”